According to Repligen
's latest financial reports the company has a price-to-book ratio of 4.72.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 5.09 | 3.51% |
2022-12-31 | 4.92 | -41.2% |
2021-12-31 | 8.37 | 22.02% |
2020-12-31 | 6.86 | 50.85% |
2019-12-31 | 4.55 | 20.81% |
2018-12-31 | 3.76 | 40.83% |
2017-12-31 | 2.67 | -56.75% |
2016-12-31 | 6.18 | -18.64% |
2015-12-31 | 7.59 | 30.75% |
2014-12-31 | 5.81 | 38.56% |
2013-12-31 | 4.19 | 80% |
2012-12-31 | 2.33 | 48.22% |
2011-12-31 | 1.57 | -25.05% |
2010-12-31 | 2.10 | 11.94% |
2009-12-31 | 1.87 | 13.48% |
2008-12-31 | 1.65 | -45.55% |
2007-12-31 | 3.03 | -10.17% |
2006-12-31 | 3.37 | -27.58% |
2005-12-31 | 4.66 | 32.78% |
2004-12-31 | 3.51 | -18.64% |
2003-12-31 | 4.31 | 35.83% |
2002-12-31 | 3.17 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Pfizer PFE | 1.61 | -65.91% | ๐บ๐ธ USA |
Thermo Fisher Scientific TMO | 4.67 | -1.04% | ๐บ๐ธ USA |
General Electric GE | 6.22 | 31.64% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 3.09 | -34.68% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | 1.30 | -72.41% | ๐บ๐ธ USA |
Novavax NVAX | -0.7979 | -116.89% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | 6.12 | 29.67% | ๐บ๐ธ USA |
Bio-Techne TECH | 5.13 | 8.64% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | 3.11 | -34.25% | ๐บ๐ธ USA |
Charles River Laboratories
CRL | 3.22 | -31.78% | ๐บ๐ธ USA |